Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM.
CURRETAB vs DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Category C
Category D/X
Progestin
Progestin + Estrogen